+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration



Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration



Biological and Pharmaceutical Bulletin 40(7): 992-1001



The pharmacological profile of fimasartan, [2-n-butyl-5-dimethylamino-thiocarbonyl-methyl-6-methyl-3-{[2-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-pyrimidin-4(3H)-one, a new non-peptide angiotensin type 1 (AT1)-selective angiotensin receptor antagonist, has been investigated in a variety of in vitro and in vivo experimental models. In the present study, fimasartan showed slow dissociation and irreversible binding to AT1 subtype receptors in membrane fractions of HEK-293 cells with a Kd of 0.03 nM and a T1/2 of 63.7 min. The inhibitory effect of fimasartan on angiotensin II (Ang II)-induced contraction persisted longer after washout than that of losartan or candesartan. In conscious rats, a single dose of fimasartan (0.3, 1, or 3 mg/kg; per os (p.o.)) dose-dependently antagonized Ang II-induced pressor responses. Both orally administrated fimasartan and losartan dose-dependently decreased mean arterial pressure in furosemide-treated rats and dogs, and fimasartan administered orally at 1, 3, or 10 mg/kg reduced blood pressure in conscious spontaneously hypertensive rats. Taken together, these findings indicate that fimasartan has potent and sustained binding affinity at the AT1 receptor subtype, and reveal the molecular basis responsible for the marked lowering of blood pressure in various conscious rats and dogs models after its oral administration.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060087422

Download citation: RISBibTeXText

PMID: 28674263

DOI: 10.1248/bpb.b16-00987


Related references

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 biphenyl-4-yl-1H-benzimidazole-7-carboyxlic acid. Journal of Pharmacology & Experimental Therapeutics 266(1): 114-120, 1993

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 268(3): 1540-1547, 1994

Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 259(1): 44-51, 1991

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, -1- ethyl 2-ethoxy-1- bipenyl-4-yl-methyl-1H-benzimidazole-7-carboxylate. Journal of Pharmacology & Experimental Therapeutics 268(3): 1540-1547, 1994

OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. Journal of Pharmacology and Experimental Therapeutics 287(3): 860-867, 1998

Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. Biological and Pharmaceutical Bulletin 36(7): 1208-1215, 2013

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). Journal of Pharmacology and Experimental Therapeutics 266(1): 114-120, 1993

SR 27417, a novel, highly potent and long-acting PAF receptor antagonist. Journal of Lipid Mediators & Cell Signalling 10(1-2): 149-150, 1994

A potent long-acting imidazole-5-acrylic acid angiotensin II AT-1 receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 4(1): 23-28, 1994

SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor. Drugs of the Future 17(11): 1011-1018, 1992

HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. European Journal of Pharmacology 200(1): 179-182, 1991

Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist. European Journal Of Pharmacology. 283(1-3): 63-72, 1995

Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin II AT-1 receptor antagonist. FASEB Journal 8(4-5): A832, 1994

Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine. Journal of Pharmacology and Experimental Therapeutics 238(2): 587-593, 1986

BRL 46470A: A highly potent, selective and long acting 5-HT-3 receptor antagonist with anxiolytic-like properties. Psychopharmacology 110(3): 257-264, 1993